MétaCan
Menu
Back to cohort
Record W4399628176 · doi:10.13162/hro-ors.v11i2.5711

Implementing a Medication Switching Policy: Analysis of the Saskatchewan Biosimilars Initiative

2024· article· en· W4399628176 on OpenAlexaffvenueabout
Kirsten Fox

Bibliographic record

VenueHealth Reform Observer - Observatoire des Réformes de Santé · 2024
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBiosimilars and Bioanalytical Methods
Canadian institutionsSaskatchewan Health Authority
Fundersnot available
KeywordsBiosimilarMedicineBusinessInternal medicine

Abstract

fetched live from OpenAlex

Biologics are drugs that are uniquely created through advanced biotechnology. Biologics can be classified as either a reference biologic or a biosimilar. Reference biologics are innovator drugs whereas biosimilars are structurally similar, but not identical, to the reference biologic. Biologic drugs, especially reference biologics, are expensive and their use is steadily increasing across Canada. In response to increasing medication costs associated with the use of biologic drugs, the Saskatchewan Ministry of Health implemented the Saskatchewan Biosimilars Initiative on 20 October 2022. The Saskatchewan Biosimilars Initiative is a medication-switching policy that requires patients using a reference biologic to transition to an available biosimilar. This policy is intended to increase the uptake of biosimilars, which cost up to 50% less than the reference biologic. Similar switching policies that have been implemented internationally have produced significant cost savings to public health insurance programs. Currently, no economic data from the Saskatchewan Ministry of Health or the Drug Plan and Extended Benefits Branch is available to assess policy effectiveness. Les produits biologiques sont des médicaments créés de manière unique grâce à une biotechnologie avancée. Les produits biologiques peuvent être classés en tant que produits biologiques de référence ou biosimilaires. Les produits biologiques de référence sont des médicaments innovants, tandis que les biosimilaires sont structurellement similaires, mais pas identiques, au produit biologique de référence. Les médicaments biologiques, en particulier les médicaments biologiques de référence, sont coûteux et leur utilisation est en constante augmentation au Canada. En réponse à l’augmentation des dépenses associées à l’utilisation des médicaments biologiques, le ministère de la santé de la Saskatchewan a mis en place l’initiative des biosimilaires de la Saskatchewan le 20 octobre 2022. La Saskatchewan Biosimilars Initiative est une politique de substitution non médicale qui exige que les patients utilisant un médicament biologique de référence pour lequel existe un biosimilaire passent à ce biosimilaire. Cette politique vise à accroître l’utilisation des biosimilaires, qui coûtent jusqu’à 50 % de moins que le produit biologique de référence. Des politiques similaires de transition non médicale mises en œuvre à l’échelle internationale ont permis aux programmes publics d'assurance maladie de réaliser des économies considérables. À l’heure actuelle, le ministère de la santé de la Saskatchewan ou la Drug Plan and Extended Benefits Branch ne disposent d'aucune donnée économique permettant d’évaluer l’efficacité de la politique.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.592
Threshold uncertainty score0.832

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.003
Science and technology studies0.0010.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.045
GPT teacher head0.358
Teacher spread0.313 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes3
Has abstractyes

Explore more

Same venueHealth Reform Observer - Observatoire des Réformes de SantéSame topicBiosimilars and Bioanalytical MethodsFrench-language works237,207